Wang Lai Net Worth

The estimated Net Worth of Lai Wang is at least $301 Million dollars as of 17 May 2022. Mr Wang owns over 1,233,947 units of BeiGene Ltd stock worth over $297,404,353 and over the last 3 years he sold BGNE stock worth over $2,106,157. In addition, he makes $1,128,165 as Global Head of R&D at BeiGene Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Lai BGNE stock SEC Form 4 insiders trading

Mr has made over 12 trades of the BeiGene Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,064 units of BGNE stock worth $170,027 on 24 June 2024.

The largest trade he's ever made was exercising 1,233,947 units of BeiGene Ltd stock on 17 May 2022 worth over $4,022,667. On average, Mr trades about 82,963 units every 74 days since 2021. As of 17 May 2022 he still owns at least 1,408,498 units of BeiGene Ltd stock.

You can see the complete history of Mr Wang stock trades at the bottom of the page.

Mr. Wang Lai biography

Wang Lai is the Global Head of R&D at BeiGene Ltd.

What is the salary of Mr Lai?

As the Global Head of R&D of BeiGene Ltd, the total compensation of Mr Lai at BeiGene Ltd is $1,128,165. There are 5 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.

How old is Mr Lai?

Mr Lai is 44, he's been the Global Head of R&D of BeiGene Ltd since . There are 21 older and no younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.

What's Mr Lai's mailing address?

Lai's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.

Insiders trading at BeiGene Ltd

Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., and Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.

What does BeiGene Ltd do?

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Complete history of Mr Wang stock trades at BeiGene Ltd

BeiGene Ltd executives and stock owners

BeiGene Ltd executives and other stock owners filed with the SEC include:

• John Oyler,
  Co-Founder, Executive Chairman of the Board, Chief Executive Officer
• Xiaodong Wang,
  Co-Founder, Non-Executive Director
• Dr. Xiaodong Wang Ph.D.,
  Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director
• John V. Oyler,
  Co-Founder, Exec. Chairman & CEO
• Dr. Xiaobin Wu Ph.D.,
  Pres, COO & GM of China
• Wang Lai,
  Global Head of R&D
• Dr. Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Jane Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Heng Liang,
  CFO & Chief Strategy Officer
• Thomas Malley,
  Non-Executive Independent Director
• Qingqing YI,
  Non-Executive Independent Director
• Timothy Chen,
  Non-Executive Independent Director
• Jing-Shyh Su,
  Non-Executive Independent Director
• Donald Glazer,
  Non-Executive Independent Director
• Ranjeev Krishana,
  Non-Executive Independent Director
• Michael Goller,
  Non-Executive Independent Director
• Corazon Sanders,
  Non-Executive Independent Director
• Anthony Hooper,
  Non-Executive Director
• Hing Ling Chau,
  Company Secretary
• Jane Huang,
  Chief Medical Officer, Hematology
• Xiaobin Wu,
  General Manager - China, President
• Kevin C. Mannix,
  Sr. VP of Investor Relations.
• Mi Zhou,
  Sr. Director of Investor Relations
• Julia Wang,
  CFO & Principal Accounting Officer
• Diana Lee Francis,
  VP and Global Head of Quality & Regulatory Compliance
• Scott Samuels,
  Sr. VP & Gen. Counsel
• Craig West CFA,
  Sr. Director of Investor Relations
• Michael Garvey,
  Global Head of Technical Operations
• Daniel Maller,
  VP of Fin. & Accounting
• Jianxin Yang,
  Sr. VP, Head of Clinical Dev.
• Amy C. Peterson,
  CMO, Immuno-oncology
• Ji Li,
  EVP and Gl. Head of Bus. Dev.
• Investment Management, Ltd....,
  10% owner
• Rui Rong Yuan,
  Chief Medical Officer
• Ke Tang,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Biotech Investment Ltd Cpe ...,
  
• Wendy Xiaojun Yan,
  Sr. VP, Head of Reg. Affairs
• & Co., Inc.Merck Sharp & Do...,
  
• Chan Henry Lee,
  SVP, General Counsel
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Howard Liang,
  CFO & Chief Strategy Officer
• Inc Amgen,
  10% owner
• Lai Wang,
  Global Head of R&D
• Olivier Brandicourt,
  Director
• Julia Aijun Wang,
  Chief Financial Officer
• Margaret Dugan,
  Director
• Advisors, Ltd.Hillhouse Inv...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Titus B. Ball,
  Principal Accounting Officer
• Aaron Rosenberg,
  Chief Financial Officer